Astrazeneca Pharma India Ltd (ASTRAZEN)
🎯 Key Takeaways
- AstraZeneca Pharma India is in a high-growth phase driven by strong execution in oncology, biopharmaceuticals, and rare disease segments, supported by regulatory approvals and strategic investments in innovation. Management is focused on sustaining double-digit growth and long-term value creation through science-led initiatives, despite a challenging macro environment reflected in a 1Y return of -17.
- Revenue grew 18% QoQ to ₹683 in Q1FY27.
- ⚠️ Margin pressure is emerging as operating margins declined to 6.4% in Jun 2026 from 13.0% in Sep 2025, despite revenue growth, signaling potential cost
- Market Cap
- ₹15,719
- P/E Ratio
- 92.7
- P/B Ratio
- 18.01
- ROE
- 19.4%
- ROCE
- 26.8%
- Debt/Equity
- 0.00
- Div Yield
- 0.57%
- Promoter
- 75.0%
📖 The Story
AstraZeneca Pharma India is in a high-growth phase driven by strong execution in oncology, biopharmaceuticals, and rare disease segments, supported by regulatory approvals and strategic investments in innovation. Management is focused on sustaining double-digit growth and long-term value creation through science-led initiatives, despite a challenging macro environment reflected in a 1Y return of -17.7%.
📰 What's Happening
In Q1 FY26-27, the company achieved 30% YoY revenue growth to INR 6,828 Mn, with profit before tax at INR 510 Mn, as confirmed in the August 11, 2026 financial results filing. Key drivers included oncology, biopharmaceuticals, and rare disease segments, alongside regulatory approvals and strategic initiatives like AI-enabled lung cancer screening in Telangana and K+ Connect for hyperkalaemia management. The board approved these results and appointed Mr. Arun Krishna as Additional Director on August 12, 2026, while Ms. Bhavana Agrawal transitioned from Executive Director to Non-Executive Director effective September 1, 2026, following her resignation as CFO. Shareholders endorsed all AGM resolutions on August 10, 2026, confirming board continuity.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 559 | 612 | 579 | 683 |
| Operating Profit | 73 | 41 | 55 | 44 |
| OPM % | 13.0% | 6.7% | 9.6% | 6.4% |
| Net Profit | 54 | 33 | 45 | 38 |
| EPS | ₹21.69 | ₹13.04 | ₹17.95 | ₹15.17 |
Revenue has grown sequentially from INR 559 Cr in Sep 2025 to INR 612 Cr in Dec 2025, then to INR 579 Cr in Mar 2026, and sharply to INR 683 Cr in Jun 2026, reflecting strong momentum. However, operating margins have fluctuated, declining from 13.0% in Sep 2025 to 6.4% in Jun 2026, indicating rising cost pressures despite top-line growth. Net profit rose to INR 38 Cr in Jun 2026 from INR 33 Cr in Dec 2025 but fell from INR 54 Cr in Sep 2025, suggesting margin compression offsetting volume gains. EPS followed a similar trend, peaking at INR 21.69 in Sep 2025 and declining to INR 15.17 in Jun 2026.
🔮 Management Outlook & What's Next
Management expects continued double-digit growth and sustainable long-term value creation through strategic investments in oncology, rare disease, and cardiovascular care initiatives, as stated in the August 11, 2026 financial results filing. No specific forward guidance on margins or capex was provided, but the emphasis remains on innovation and science-driven expansion to maintain momentum in key therapeutic areas.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 |
| Reserves | 765 | 674 | 868 | 794 |
| Borrowings | 36 | 17 | 0 | 35 |
| Total Liabilities | 1,518 | 1,241 | 1,989 | 1,615 |
| Fixed Assets | 64 | 67 | 117 | 40 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 1,518 | 1,241 | 1,989 | 1,615 |
The balance sheet shows a strong equity base of INR 5 Cr with reserves growing from INR 765 Cr in March 2025 to INR 868 Cr in March 2026, indicating healthy retained earnings. Borrowings remain minimal at INR 35 Cr in March 2026, down from INR 36 Cr a year ago, reflecting a conservative capital structure. Total assets increased to INR 1,989 Cr in March 2026 from INR 1,518 Cr in March 2025, suggesting ongoing investment in operations without significant leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | -15 |
| Investing | +19 |
| Financing | -92 |
| Net Cash Flow | -88 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 75.0% | 75.0% | 75.0% | 75.0% |
| FII | 2.7% | 2.7% | 2.8% | 2.7% |
| DII | 5.3% | 5.6% | 5.8% | 6.1% |
| Public | 14.4% | 14.1% | 13.9% | 13.8% |
| # Shareholders | 32,914 | 31,551 | 29,007 | 29,338 |
Institutional holding has remained relatively stable, with FII ownership slightly declining from 2.78% in Q4FY26 to 2.68% in Q1FY27, while DII increased from 5.56% to 6.08% over the same period, indicating growing interest from domestic institutional investors. The promoter holding remains steady at 75%, and the number of public shareholders has slightly decreased, but retail participation remains broad with over 29,000 shareholders.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
Margin pressure is emerging as operating margins declined to 6.4% in Jun 2026 from 13.0% in Sep 2025, despite revenue growth, signaling potential cost inflation or pricing pressures. Regulatory and execution risks in new initiatives like AI-enabled screening and international market expansion could impact timelines and ROI. Additionally, the company's high P/E of 102.7 and negative 1Y return suggest valuation sensitivity to growth sustainability amid a challenging macro environment.
📋 Recent Filings
- 🔴 Announcement2026-09-18AstraZeneca Pharma India disclosed a penalty of Rs.1.88 lakh imposed by the Registrar of Companies for delayed filing of Form MR-2 related to Dr. Sanj…
- 🔴 Announcement2026-09-15AstraZeneca Pharma India announced the resignation of Dr. Sandeep Arora, Director of Medical Affairs and Rare Disease Business Unit, effective Septemb…
- Announcement2026-09-15AstraZeneca Pharma India Ltd announced that its trading window will close on September 16, 2026, to comply with insider trading regulations, remaining…
- 🔴 Announcement2026-09-02AstraZeneca Pharma India disclosed its ESG rating of 64 from Crisil ESG Ratings, based on FY2026 public data, without company engagement or endorsemen…
- Announcement2026-08-25AstraZeneca Pharma India Limited disclosed that the Delhi High Court stayed an NPPA demand notice alleging overcharging on Betaloc-50 until February 1…
- Announcement2026-08-24AstraZeneca Pharma India Limited disclosed its ESG rating of 57 from Crisil ESG Ratings, based on publicly available information, without any engageme…
- Announcement2026-08-21AstraZeneca Pharma India Limited announced a scheduled one-on-one virtual meeting with an institutional investor on August 26, 2026, to discuss ongoin…
- Announcement2026-08-15AstraZeneca Pharma India Limited announced a scheduled one-on-one virtual meeting with institutional investors on August 19, 2026, to discuss its busi…
- 🟡 Board Meeting2026-08-12AstraZeneca Pharma India Limited announced that all resolutions proposed at its 47th Annual General Meeting held on August 10, 2026 via video conferen…
- 🔴 Financial Results2026-08-11AstraZeneca Pharma India reported 30% YoY revenue growth to INR 6,828 Mn in Q1 FY2026-27, driven by oncology, biopharmaceuticals, and rare disease seg…
🧠 Analyst's Read
AstraZeneca Pharma India is executing a robust science-driven growth strategy with strong segmental momentum, but near-term margin volatility and high valuation warrant close monitoring of cost discipline and execution of new initiatives. The company's long-term outlook remains anchored in oncology and rare disease leadership, though near-term performance will depend on operational efficiency and macro conditions.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ASTRAZEN files new disclosures
Track ASTRAZEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ASTRAZEN — FreeFree account · 2 AI queries/day